Terumo Medical Corporation Applauds ACC/AHA/SCAI Decision to Designate Radial Access Class 1, Level of Evidence A

SOMERSET,N.J.,Jan. 12,2022 -- Terumo Medical Corporation (TMC) applauds the publication of updated guidelines from the American College of Cardiology (ACC),American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI) that give radial access a Class 1 (Level of Evidence A) indication for patients undergoing percutaneous coronary intervention (PCI) for both acute coronary syndrome (ACS) and stable ischemic heart disease (SIHD).*

With the updated guidelines,it is expected that more physicians will expand their use of radial access. A radial approach to coronary care procedures produces demonstrably better outcomes for patients and hospitals,including these well-established and recognized benefits:

Reduction in access-site bleeding and other vascular complications;

Early post-procedure ambulation;

Increased patient comfort and satisfaction;

Potential improved financial and operational outcomes through facilitation of same-day discharge.

Celebrating 30 years of engineering and manufacturing state-of-the-art radial access products,as well as training and educating thousands of healthcare providers on the procedure,Terumo is a pioneer in radial access.

"As the first company to design and manufacture products specifically for radial access,Terumo has been a leader in supporting the important shift to the 'radial first' approach to interventional cardiology," said Dr. Michael Martinelli,TMC's Chief Medical Officer. "Our strategy,our product portfolio,our support for clinical trials,and especially our educational outreach to healthcare providers have provided an essential platform for the growth and success of radial access for coronary intervention and as such contributed significantly to improved outcomes for millions of patients worldwide."

"Thedecisionof the ACC,AHA and SCAIto recognize radial access with this level of clinical evidencewill lead to improved patient outcomes,which is ourprimarygoal as a company and an industry,"addedChris Pearson,Executive Vice President,Commercial Operations,Terumo Interventional Systems–North America. "We at Terumo are proud to have played a significant role in bringing radial access to the forefront of clinical practice."

*2021 ACC/AHA/SCAIGuideline for Coronary Artery Revascularization: Executive Summary:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines; J Am Coll Cardiol.Dec 09,2021.E-published DOI: 10.1016/j.jacc.2021.09.005

About Terumo Medical Corporation

Terumo Medical Corporation (TMC) is a subsidiary of Terumo Corporation,founded in 1972 as the United States expansion of our larger Tokyo-based parent company. For nearly 50 years,TMC has continued the Terumo mission of offering the best possible solutions to healthcare providers and the people they serve. TMC provides products and services across four divisions: Terumo Health Outcomes,which provides healthcare systems with solutions designed to reduce care variation,improve quality metrics,minimize cost and maximize revenue; Terumo Interventional Systems (TIS),which offers solutions for entry site management,embolization and lesion access; Terumo Medical Products (TMP),which provides devices for injection and infusion therapy; and Terumo Pharmaceutical Solutions (TPS),which develops drug delivery devices. For more information,visit www.terumomedical.com.

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally,Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now,its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions,blood transfusion and cell therapy technology,to medical products essential for daily clinical practice such as transfusion systems,diabetes care,and peritoneal dialysis treatments. Terumo will further strive to be of value to patients,medical professionals,and society at large. More information can be found at www.terumo.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-medical-corporation-applauds-accahascai-decision-to-designate-radial-access-class-1-level-of-evidence-a-301458739.html